Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
XELOX regimen had a more favorable toxicity profile compared to cisplatin for patients with
advanced gastric cancer. The safety profile of oxaliplatin makes it an ideal candidate for
combination therapy. However, oxaliplatin induce sensory neuropathy, a cumulative,
dose-related toxicity. It may therefore be possible to devise capecitabine maintenance
regimen which achieves maximum treatment effect before cumulative neurotoxicity appears. We
study that randomized Phase III study of Xelox (Capecitabine plus Oxaliplatin) followed by
maintenance Capecitabine or Observation in the gastric cancer patients of stable disease
after 6 cycle 1st line of XELOX chemotherapy .